SER

1.1206.67%
JM

J. Milton Harris

Co-Founder, Director Emeritus & Chair of Scientific Advisory Board

Dr. J. Milton Harris, Ph.D., was Director of Serina Therapeutics, Inc. from March 26, 2024 until February 2025 and serves as its Director Emeritus & Chair of Scientific Advisory Board from February 2025 Dr. Harris has played an instrumental role in the development of Serina's POZ Platform, providing leadership and scientific expertise that have shaped the company's pipeline and clinical development. In his new role, he is to provide continued guidance to Serina's research and development efforts and Dr. Harris is Co-Founder & was Chairman of the Board of Serina Therapeutics, Inc. Dr. Harris was Chief Scientific Officer - Nektar AL of Nektar Therapeutics. Dr. Harris joined the Nektar Therapeutics in 2001. He served as Chair of the Legacy Serina Board of Directors since he co-founded Legacy Serina in 2006. Dr. Harris served as the President of Nektar AL from 2001 to March 2004. He is a Member of the Swedish Academy of Engineering Sciences. Dr. Harris has many years of experience as a senior life sciences executive. Prior to founding Legacy Serina, he was the Founder and Chief Executive Officer of Shearwater. Shearwater was founded by Dr. Harris in 1992 and sold in 2001 to Inhale Therapeutics, Inc. (Inhale Therapeutics, Inc., subsequently changed its name to Nektar Therapeutics, Inc.). Shearwater successfully patented, manufactured and partnered PEG technology that enabled multiple drug products including Neulasta® (Amgen) and Pegasys® (Roche). Dr. Harris has also served on the board of directors of HudsonAlpha Institute for Biotechnology since its founding in 2004. Dr. Harris earned a B.S. from McGill University, where he also was awarded an honorary Sc.D. and a Ph.D. from the Massachusetts Institute of Technology. Dr. Harris has co-authored more than 200 publications and is a co-inventor on more than 75 patents.

Positions